Skip to main content

Rogers Corp (ROG)

Electronics Information Technology
Stock AI

Financial Metrics

Price to Earnings79.11x
Revenue Growth (1Y)4.9%
Debt to Equity0.0033x

Strengths

Stock Chart

Valuation

Rogers Corp is overvalued

News

All
Press Releases
News
Filings
10-Q Quarterly Report for 2026 Q2
July 29, 202610-Q Quarterly Report for 2026 Q2
Rogers Corporation Reports Second Quarter 2026 Results
July 28, 2026Rogers Corporation Reports Second Quarter 2026 Results
Rogers Corporation Releases Its 2026 Sustainability Report
July 16, 2026Rogers Corporation Releases Its 2026 Sustainability Report
Rogers Corporation Schedules Second Quarter 2026 Earnings Call for July 28
July 14, 2026Rogers Corporation Schedules Second Quarter 2026 Earnings Call for July 28
Rogers Corporation Announces Addition of Brett Cope and Eric Starkloff to Its Board of Directors
May 07, 2026Rogers Corporation Announces Addition of Brett Cope and Eric Starkloff to Its Board of Directors
10-Q Quarterly Report for 2026 Q1
April 29, 202610-Q Quarterly Report for 2026 Q1
Rogers Corporation Reports First Quarter 2026 Results
April 28, 2026Rogers Corporation Reports First Quarter 2026 Results
Rogers Corporation Schedules First Quarter 2026 Earnings Call for April 28
April 14, 2026Rogers Corporation Schedules First Quarter 2026 Earnings Call for April 28
10-K Annual Report for 2025 FY
February 19, 202610-K Annual Report for 2025 FY
Rogers Corporation Reports Fourth Quarter and Full Year 2025 Results
February 17, 2026Rogers Corporation Reports Fourth Quarter and Full Year 2025 Results
Rogers Corporation Schedules Fourth Quarter 2025 Earnings Call for February 17
February 03, 2026Rogers Corporation Schedules Fourth Quarter 2025 Earnings Call for February 17
10-Q Quarterly Report for 2025 Q3
October 30, 202510-Q Quarterly Report for 2025 Q3
Rogers Corporation Reports Third Quarter 2025 Results
October 29, 2025Rogers Corporation Reports Third Quarter 2025 Results
Rogers Corporation Announces Transition of Board Chair and Plans to Add New Independent Director
October 16, 2025Rogers Corporation Announces Transition of Board Chair and Plans to Add New Independent Director
Rogers Corporation Schedules Third Quarter 2025 Earnings Call for October 29
October 15, 2025Rogers Corporation Schedules Third Quarter 2025 Earnings Call for October 29
Starboard Value Builds Over 9% Stake in Engineering-Materials Maker Rogers
August 06, 2025Starboard Value Builds Over 9% Stake in Engineering-Materials Maker Rogers
Starboard Value Builds Over 9% Stake in Engineering-Materials Maker Rogers
August 06, 2025Starboard Value Builds Over 9% Stake in Engineering-Materials Maker Rogers
10-Q Quarterly Report for 2025 Q2
August 01, 202510-Q Quarterly Report for 2025 Q2
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
July 31, 2025Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
Rogers Corporation Reports Second Quarter 2025 Results
July 31, 2025Rogers Corporation Reports Second Quarter 2025 Results
Rogers Corporation Schedules Second Quarter 2025 Earnings Call for July 31
July 17, 2025Rogers Corporation Schedules Second Quarter 2025 Earnings Call for July 31
Rogers Corporation Announces CEO Transition
July 14, 2025Rogers Corporation Announces CEO Transition
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
May 13, 2025Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
Roche and Genentech Announce New North Carolina Manufacturing Facility
May 12, 2025Roche and Genentech Announce New North Carolina Manufacturing Facility
10-Q Quarterly Report for 2025 Q1
April 30, 202510-Q Quarterly Report for 2025 Q1
Rogers Corporation Reports First Quarter 2025 Results
April 29, 2025Rogers Corporation Reports First Quarter 2025 Results
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
April 25, 2025New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
Rogers Corporation Schedules First Quarter 2025 Earnings Call for April 29
April 15, 2025Rogers Corporation Schedules First Quarter 2025 Earnings Call for April 29
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
April 03, 2025Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
April 02, 2025Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
March 05, 2025FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
March 03, 2025FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
March 02, 2025Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
10-K Annual Report for 2024 FY
February 26, 202510-K Annual Report for 2024 FY
Rogers Corporation Reports Fourth Quarter and Full Year 2024 Results
February 19, 2025Rogers Corporation Reports Fourth Quarter and Full Year 2024 Results
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
February 12, 2025FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Rogers Corporation Schedules Fourth Quarter 2024 Earnings Call for February 19
February 11, 2025Rogers Corporation Schedules Fourth Quarter 2024 Earnings Call for February 19
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
February 07, 2025New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
February 04, 2025FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
January 28, 2025Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
10-Q Quarterly Report for 2024 Q3
October 25, 202410-Q Quarterly Report for 2024 Q3
10-Q Quarterly Report for 2024 Q2
July 26, 202410-Q Quarterly Report for 2024 Q2
10-Q Quarterly Report for 2024 Q1
April 26, 202410-Q Quarterly Report for 2024 Q1
10-K Annual Report for 2023 FY
February 27, 202410-K Annual Report for 2023 FY
10-Q Quarterly Report for 2023 Q3
October 27, 202310-Q Quarterly Report for 2023 Q3
10-Q Quarterly Report for 2023 Q2
August 04, 202310-Q Quarterly Report for 2023 Q2
10-Q Quarterly Report for 2023 Q1
April 28, 202310-Q Quarterly Report for 2023 Q1
10-K Annual Report for 2022 FY
March 01, 202310-K Annual Report for 2022 FY
10-Q Quarterly Report for 2022 Q3
November 09, 202210-Q Quarterly Report for 2022 Q3
10-Q Quarterly Report for 2022 Q2
August 05, 202210-Q Quarterly Report for 2022 Q2
10-Q Quarterly Report for 2022 Q1
April 29, 202210-Q Quarterly Report for 2022 Q1
10-K Annual Report for 2021 FY
February 22, 202210-K Annual Report for 2021 FY
10-Q Quarterly Report for 2021 Q3
November 08, 202110-Q Quarterly Report for 2021 Q3

A. Company Overview

Rogers Corporation is an advanced materials company that designs, develops, manufactures, and sells high-performance engineered materials and components. The company primarily serves industries that require reliable and specialized solutions, including automotive, aerospace, telecommunications, and renewable energy. Rogers has established a global presence with its headquarters located in Chandler, Arizona, and operates through various manufacturing and administrative facilities across North America, Europe, and Asia.

B. Business Segments

Rogers Corporation operates through two primary business segments: Advanced Electronics Solutions (AES) and Elastomeric Material Solutions (EMS). These segments reflect the company's focus on high-performance materials used in sophisticated applications.

Advanced Electronics Solutions (AES)

The AES segment focuses on producing circuit materials, ceramic substrate materials, busbars, and cooling solutions. These products are essential for various applications, including electric vehicles (EVs) and hybrid electric vehicles (HEVs), advanced driver-assistance systems (ADAS), aerospace and defense communication systems, renewable energy technologies (such as solar and wind), wireless infrastructure, and industrial machinery. AES products are recognized for their performance characteristics and functional advantages that distinguish them from conventional materials.

Key trade names under the AES segment include:

  • curamik®
  • ROLINX®
  • RO4000® Series
  • RT/duroid®

As of December 31, 2023, AES operates facilities in locations such as Chandler, Arizona; Rogers, Connecticut; Suzhou, China; and Eschenbach, Germany.

Elastomeric Material Solutions (EMS)

The EMS segment specializes in engineered material solutions that encompass polyurethane and silicone materials. These materials are utilized in cushioning, sealing, and vibration management applications across numerous industries including automotive, mass transit, medical, and portable electronics. The solutions provided by EMS are integral for various functions, such as thermal management in electronic components.

Popular trade names in the EMS segment include:

  • PORON®
  • BISCO®
  • DeWAL®

EMS facilities are located in various regions including Rogers, Connecticut; Carol Stream, Illinois; and Evergem, Belgium.

Other Operating Segment

In addition to AES and EMS, Rogers Corporation has an Other segment which includes elastomer components for general industrial markets and level sensing floats for automotive applications. These products are marketed under the ENDUR® and NITROPHYL® trade names.

C. Joint Ventures

Rogers Corporation is engaged in joint ventures that enhance its market reach. Notably, it owns 50% of two joint ventures:

  1. RIC: Based in Japan, focusing on the development of PORON® products.
  2. RIS: Located in China, providing PORON® solutions primarily for customers in Asia.

Both ventures are in collaboration with INOAC Corporation, which holds the other 50%.

D. Sales and Competition

Rogers Corporation boasts a diverse customer base, with approximately 3,200 clients worldwide, primarily consisting of Original Equipment Manufacturers (OEMs) and component suppliers. The company employs a technical sales and marketing approach, providing collaborative design engineering and product development support. This focus on technical service and high-quality products is crucial in competing with both large multinational corporations and smaller regional producers.

The competitive landscape emphasizes innovation, product reliability, and technical support as vital factors. Rogers Corporation differentiates itself from competitors through its reputation for innovation and high-performance materials.

E. Research and Development

Rogers Corporation values innovation as a cornerstone of its business strategy. The company invests heavily in research and development (R&D) to keep pace with rapid technological changes across its target industries. The Rogers Innovation Centers, located in strategic locations including Massachusetts, Germany, and China, are dedicated to the early stages of technical development, aiming to produce market-leading materials.

F. Intellectual Property

The company maintains a robust portfolio of patents, licenses, and trademarks, which are essential for its competitive stance in the industry. These protections, combined with proprietary technologies and trade secrets, are viewed as critical to ensuring the company’s future success and market advantage.

G. Manufacturing and Raw Materials

The manufacturing process at Rogers Corporation relies extensively on specific raw materials such as copper, polytetrafluoroethylene, and various polymers. Some of these materials are sourced from sole or limited suppliers, which poses risks related to supply chain stability and price volatility.

H. Seasonality

Rogers Corporation's operations are generally not subject to significant seasonal fluctuations, aside from minor seasonal trends related to consumer-product cycles. This stability allows for consistent production and planning throughout the year.

Stock Infos

SectorInformation Technology
IndustryElectronics
CEOR. Colin Gouveia

Dividends

Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.